Shares of iHuman Inc. (IH), a biopharmaceutical company focused on transforming medicines, skyrocketed 6.54% in pre-market trading on Monday. The surge came after the company reported impressive financial results for the fourth quarter and full year 2024, driven by strong sales of its flagship product Lumryz, and reaffirmed its 2025 guidance.
The key highlights that fueled the stock rally include a 158% year-over-year increase in Lumryz sales to $50.4 million in Q4 2024, taking the full-year total to $169.1 million. Additionally, iHuman reiterated its 2025 guidance, anticipating the number of patients on Lumryz to increase to 3,300-3,500 by year-end, generating net product revenue of $240-$260 million and positive cash flow of $20-40 million.
iHuman is executing multiple initiatives to accelerate patient demand for Lumryz, such as expanding its field sales team, doubling its reimbursement team, providing more direct support to patients and physicians, and adding patient ambassadors. The company is also making progress in its pivotal Phase 3 trial for idiopathic hypersomnia (IH), which could further solidify its leadership in sleep medicine.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。